Wall Street Signals: Pressure BioSciences Inc. (PBIO) New Management Hire to Drive Revenue Growth, Advance Commercialization Programs

Pressure BioSciences Inc. (PBIO) New Management Hire to Drive Revenue Growth, Advance Commercialization Programs

Pressure BioSciences (OTCQB: PBIO), a pioneer in the advancement and offer of comprehensively empowering, weight-based instruments, consumables, and stage arrangements, as of late named Dr. Bradford A. Youthful as its senior VP and boss business officer. An article talking about the organization's ongoing arrangement peruses, "Youthful joins the Pressure BioSciences supervisory crew with a strong pioneering foundation and the experience of giving official dimension counseling to key arranging, item improvement and commercialization to different biomedical, analytic and pharmaceutical organizations. In his new position as senior VP and boss business officer, he will assume a basic job in propelling the organization's commercialization projects and by and large vital arranging, with a view toward building up new or potentially improved income openings and critical associations. … More explicitly, Young will advance the organization's instruments, consumables and innovation stages with synergistic organizations around the world, with an objective of coordinating Pressure BioSciences' items into their contributions. These sorts of joint efforts and associations could result in real volume deals, empowering the organization to essentially help its income."

To view the full article, visit Pressure BioSciences Inc.

About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.